CHAIRMAN OF THE BOARD
Dr. Reinhard Ambros has held international leadership positions in venture capital, corporate strategy, BD&L and pharmaceutical product development. From 2005 through 2017, Reinhard developed and led the Novartis Venture Fund to become one of the largest corporate biotechnology venture funds in the life sciences industry. Previously, he served as head of group strategic planning and BD&L for cardiovascular and metabolic diseases for Novartis Corporation and Novartis Pharma AG, respectively. Reinhard serves on the boards of public and private biotechnology companies in Europe and the United States, and as an advisor to German and Swiss Government Biotechnology Funds.
Dr. Daniel Vasella served as Chairman of Novartis AG, a leading global medicines company, from 1999 until 2013 and as Chief Executive Officer of Novartis from 1996 to 2010. Previously, Daniel held the positions of Chief Executive Officer, Chief Operating Officer, Senior Vice President, Head of Worldwide Development, and Head of Corporate Marketing at Sandoz Pharma Ltd. He currently is currently working as a director, strategic advisor, and coach to senior executives, and serves on the boards of PepsiCo, American Express Company, SciClone Pharmaceuticals, and several biotech companies.
Dr. Michael Baran is Executive Director, Pfizer Worldwide Research and Development and a Partner at Pfizer Ventures, where he is responsible for identifying, evaluating, making and managing equity investments aligned with the strategy of Pfizer. Prior to his current position, Mike held roles in R&D portfolio strategy as well as managing scientific affairs for the R&D President’s office at Pfizer. Mike joined Pfizer from Nexomics Biosciences, a structural biology biotech company which he co-founded. He previously worked within the NIH Protein Structure Initiative’s Northeast Structural Genomics Consortium coordinating protein structure production efforts.
Shelley Chu is a Partner with Lightspeed Venture Partners and has two decades of venture investing and operating experience in the biopharmaceutical industry. At Lightspeed, Shelley leads the firm’s biotech investments from seed to late stage. Previously, Shelley was at Gilead, where she led R&D strategy across all therapeutic areas and business development in immuno-oncology and HBV. Shelley serves on the boards of numerous biotechnology companies and on the scientific advisory board for BioCentury.
Dr. Markus Hosang is a General Partner of BioMedPartners AG. Before joining BioMedPartners, Markus was a Venture Partner at MPM Capital, where he was co-responsible for European deal flow, managed MPM’s European office in Munich, and served on the boards of several portfolio companies. Prior to joining MPM, Markus was at Roche, where he served for nearly 20 years in several senior management positions in the Pharma R&D organization, including VP and Director of the International Pharma Research Strategy Unit and Chief of Staff to the President of Roche Global R&D.
Dr. Andreas Jurgeit is a Partner with the life science team of GIMV, a publicly listed (Euronext:GIMV) private equity and venture capital investor.
Previously, Andreas worked with the venture capital arm of Lundbeckfonden and at Merck Ventures where he was responsible for investments and company creation in Europe, the United States, and Israel. Andreas started his career at Redalpine Venture Partners and has operational experience in drug discovery, business development, and M&A.
Marcos Milla is a Venture Partner with Samsara BioCapital. Previously, Marcos was the Head of Synthorx, a Sanofi company, and was the Chief Scientific Officer of Synthorx until its acquisition by Sanofi. Marcos has over 25 years of biopharmaceutical development experience across the areas of autoimmunity and inflammation, immuno-oncology, and neurosciences and pain, having held industry positions at Adaptive Biotechnologies, Janssen R&D, Roche, and GlaxoSmithKline, and a faculty appointment at the Perelman School of Medicine of the University of Pennsylvania. Marcos is currently on the faculty of Skaags School of Pharmacy and Pharmaceutical Sciences of University of California – San Diego.
Dr. Joseph Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently President, Chief Medical Officer, and a Director of Medikine. Prior to Medikine, Joe was Executive Vice President and Chief Medical Officer of Mirati Therapeutics. His previous roles include Chief Medical Officer of Synthorx, a company acquired by Sanofi, and Chief Medical Officer of ARMO Biosciences, an immuno-oncology company acquired by Eli Lilly. Earlier in his career, Joe was Chief Medical Officer of EMD Serono, the North American subsidiary of Merck KGaA, and Vice President and Head of US Medical Oncology at Bristol-Myers Squibb.
CEO & DIRECTOR
Sean R. Smith has been CEO and a board member of ImmunOs since 2017. Prior to ImmunOs, Sean spent over 15 years at MSD/Merck and Co. in positions of increasing responsibility in commercial leadership, cross-departmental management, business development, and country and regional operations with broad exposure to multiple therapeutic areas, including early-stage clinical, in-line, and launch portfolios in hospital/specialty, infectious disease, general medicine, and vaccines.